# DESCRIPTION

## CROSS-REFERENCE(S) TO RELATED APPLICATION(S)

- claim benefit of provisional application

## STATEMENT OF GOVERNMENT LICENSE RIGHTS

- disclose government support

## BACKGROUND

- introduce nucleosomes
- describe oncohistones
- discuss histone fold domain mutations
- introduce short histone H2A variants
- describe H2A.B's role in testis
- propose oncohistone activity of sH2As

## SUMMARY

- introduce method for treating lymphoma
- describe detecting sH2A expression
- administer anthracycline agent
- introduce method for inducing cytotoxicity
- describe administering anthracycline agent
- introduce method to inhibit cancer cell proliferation
- describe detecting sH2A expression and administering anthracycline agent

## DETAILED DESCRIPTION

- introduce sH2A histone variants
- describe association with nucleosome destabilization and alternate splicing
- describe aberrant sH2A upregulation in cancers
- posit sH2As as novel class of oncohistones
- describe method for treating lymphoma
- define lymphoma
- specify types of lymphoma
- describe preferred embodiments for treating Hodgkin's lymphoma
- describe embodiments for treating adult or childhood forms of lymphoma
- describe method steps: collecting sample, detecting sH2A expression, administering anthracycline agent
- specify sH2A variant: H2A.B
- describe amino acid sequences of H2A.B variants
- define "having" or "suspected of having" lymphoma
- describe sample types: blood, serum, plasma, tissue
- define detecting sH2A expression level
- describe methods for detecting sH2A expression
- describe threshold for detection
- describe administering anthracycline agent
- define anthracycline agent
- describe mechanisms of action of anthracyclines
- describe examples of anthracyclines and analogs
- describe therapeutically effective dose of anthracycline agent
- describe dosing schedules
- describe routes of administration
- describe method of inducing cytotoxicity in lymphoma cell

### Additional Definitions

- define terms used in the art
- define "or" in claims
- define "a" and "an" in claims
- define "comprise" and "comprising"
- define "about"
- define "subject", "individual", and "patient"
- define "treating" and grammatical variants
- define "therapeutic effect"
- define sequence identity
- incorporate publications by reference

### EXAMPLES

- introduce examples
- describe aberrant sH2A upregulations in cancers
- compare sH2A sequences to canonical H2A
- analyze oncohistone features in sH2As
- show conservation of oncohistone-like changes
- imply functional consequences of oncohistone-like changes
- describe H2A.B reactivation in various cancers
- analyze H2A.B expression in TCGA dataset
- show H2A.B expression in DLBCLs
- analyze H2A.B expression in B-ALL datasets
- show H2A.B expression in CCLE dataset
- compare H2A.B expression across cancers
- investigate causes of H2A.B induction in cancer
- analyze X-chromosome ploidy in H2A.B-expressing samples
- investigate expression profiles of individual H2AFB loci
- show local activation of individual H2AFB paralogues
- compare transcriptomes of H2AFB1-reactivated and H2AFB2/3-reactivated samples
- identify commonly up- or down-regulated genes
- analyze expression of other genes associated with H2A.B expression
- show lack of co-upregulation of other testis-specific histone variants
- analyze expression of histone chaperone NAP1
- investigate chromatin consequences of NAP1 expression
- identify Cancer-Testis Antigens associated with H2A.B expression
- analyze CTA expression in H2A.B-reactivated cancers
- show CTA upregulation in H2A.B-expressing HNSCs, LUSCs, and UCECs
- analyze CTA expression in B-ALL datasets
- investigate association of H2A.B expression with immune infiltrates
- analyze immune cell markers in H2A.B-expressing tumors
- show lack of excess immune infiltrates in H2A.B-positive TCGA specimens
- identify H2A.B-positive cancer cell lines
- describe H2A.B's role in RNA binding and splicing
- analyze splicing patterns in H2A.B-reactivated and silent tumors
- show reduced utilization of alternative "cassette exons" and APA sites
- analyze splicing patterns in B-ALL datasets
- show decrease in retained introns in B-ALL datasets
- conclude H2A.B expression is associated with splicing dysfunction
- discuss common splicing features among cancers
- discuss context-specific splicing features
- summarize results
- conclude H2A.B expression is associated with cancer
- introduce oncohistone mutations
- motivate H2A.B expression in cancers
- describe nucleosome instability
- explain RNA pol II elongation
- discuss alternative splicing
- relate to oncogene expression
- describe histone dynamics and transcription
- discuss DLBCLs and H2A.B expression
- introduce H2AFB/-gRNAs in cancer cells
- discuss histone mutations and H2A.B expression
- introduce sH2A-derived short peptides
- describe global splicing dysregulation
- align sH2A sequences
- perform genome annotation and RNA-seq read mapping
- estimate gene and isoform expression
- create RNA-seq coverage plots
- analyze somatic mutations
- collate mutations in canonical histones
- define recurrent mutations
- perform differential gene expression and splice event analyses
- determine statistical significance
- predict H2A variant candidate T cell epitopes
- describe H2A.B variant expression in testis
- analyze large-scale transcriptomic datasets
- confirm H2A.B expression in cancer cells
- analyze Cancer Cell Line Encyclopedia
- describe loss of H2A.B expression
- perform genome-wide CRISPR screens
- target H2A.B expression
- analyze dependency scores
- describe shRNA-induced H2A.B loss
- analyze proliferation in DLBCL, HL, and ALCL cell lines
- describe aclarubicin's cytotoxicity
- compare aclarubicin to etoposide and doxorubicin
- assess DNA damage
- analyze additional lymphoma cell lines
- conclude aclarubicin's side effect profile

